Morgan Stanley lowered the firm’s price target on Akoya Biosciences (AKYA) to $1.14 from $3 and keeps an Equal Weight rating on the shares. The firm is updating its model for Akoya’s Q1 results and the amended merger agreement proposed by Quanterix (QTRX), the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Cautious Outlook for Akoya Biosciences Amidst Competitive Pressures and Promising Long-Term Potential
- Akoya Biosciences Reports Q1 2025 Financial Results
- Akoya Biosciences price target lowered to $1.08 from $1.80 at Canaccord
- Cautious Hold Rating on Akoya Biosciences Amid Financial and Industry Challenges
- Quanterix price target lowered to $12 from $15 at Canaccord